Palisade Bio, Inc. financial data

Symbol
PALI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
7750 El Camino Real, Suite 5200, Carlsbad, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Seneca Biopharma, Inc. (to 4/26/2021), Neuralstem, Inc. (to 1/23/2020)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 389 % -43.6%
Debt-to-equity 34.1 % +92.4%
Return On Equity -169 % -89.1%
Return On Assets -126 % -66%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.4M shares -65.6%
Common Stock, Shares, Outstanding 2.77M shares +348%
Entity Public Float 4.3M USD -62.9%
Common Stock, Value, Issued 27K USD +350%
Weighted Average Number of Shares Outstanding, Basic 1.42M shares +211%
Weighted Average Number of Shares Outstanding, Diluted 1.42M shares +211%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 16M USD
General and Administrative Expense 5.8M USD -6.55%
Operating Income (Loss) -14.9M USD -13.7%
Nonoperating Income (Expense) 421K USD -45.3%
Net Income (Loss) Attributable to Parent -14.4M USD -17.4%
Earnings Per Share, Basic -10.2 USD/shares +62.3%
Earnings Per Share, Diluted -10.2 USD/shares +62.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.82M USD -21%
Accounts Receivable, after Allowance for Credit Loss, Current 250K USD
Assets, Current 10.5M USD -21.3%
Property, Plant and Equipment, Net 3K USD -70%
Operating Lease, Right-of-Use Asset 84K USD -57.6%
Other Assets, Noncurrent 273K USD -44.3%
Assets 10.9M USD -22.6%
Accounts Payable, Current 1.11M USD +58.3%
Employee-related Liabilities, Current 722K USD -7.2%
Accrued Liabilities, Current 1.24M USD +49.2%
Liabilities, Current 3.24M USD +25.1%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 3.39M USD +23.7%
Retained Earnings (Accumulated Deficit) 136M USD +11.9%
Stockholders' Equity Attributable to Parent 7.49M USD -33.8%
Liabilities and Equity 10.9M USD -22.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.18M USD +9.81%
Net Cash Provided by (Used in) Financing Activities 2.02M USD -54.4%
Common Stock, Shares Authorized 280M shares 0%
Common Stock, Shares, Issued 2.77M shares +348%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD -226%
Interest Paid, Excluding Capitalized Interest, Operating Activities 2K USD
Deferred Tax Assets, Valuation Allowance 32.5M USD +12.1%
Deferred Tax Assets, Gross 32.6M USD +12%
Operating Lease, Liability 122K USD -49%
Depreciation 1K USD 0%
Lessee, Operating Lease, Liability, to be Paid 128K USD -51.3%
Operating Lease, Liability, Current 90K USD -25.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 93K USD -31.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 94K USD -30.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6K USD -75%
Deferred Tax Assets, Operating Loss Carryforwards 27.4M USD +10.8%
Additional Paid in Capital 143M USD +7.98%
Share-based Payment Arrangement, Expense 633K USD +4.46%
Interest Expense 12K USD -20%